Meta-analysis: The significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 10, 2011, Pages 1087-1103

  Qi, X ^a   Yang, Z ^a   Bai, M ^a   Shi, X ^a   Han, G ^a   Fan, D ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERY THROMBOSIS; ARTICLE; BUDD CHIARI SYNDROME; CENTRAL RETINA VEIN THROMBOSIS; CEREBRAL VEIN THROMBOSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC SCREENING; HUMAN; LIVER VEIN THROMBOSIS; META ANALYSIS; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; SUPERIOR MESENTERIC ARTERY THROMBOSIS; SYSTEMATIC REVIEW; VEIN THROMBOSIS;

BUDD-CHIARI SYNDROME; GENETIC TESTING; HUMANS; JANUS KINASE 2; MASS SCREENING; MUTATION; PORTAL VEIN; VENOUS THROMBOSIS;

EID: 79954926060     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04627.x     Document Type: Article

References (54)

1. De Stefano V, Martinelli I,. Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 2010; 5: 487-94.
2. DeLeve LD, Valla DC, Garcia-Tsao G,. Vascular disorders of the liver. Hepatology 2009; 49: 1729-64.
3. Valla D, Casadevall N, Huisse MG, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988; 94: 1063-9.
4. Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985; 103: 329-34. (Pubitemid 15236564)
5. Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005; 129: 553-60. (Pubitemid 40769907)
6. Briere JB,. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin Thromb Hemost 2006; 32: 208-18.
7. Thiele J, Kvasnicka HM, Orazi A,. Bone marrow histopathology in myeloproliferative disorders-current diagnostic approach. Semin Hematol 2005; 42: 184-95. (Pubitemid 41400660)
8. Thiele J, Kvasnicka HM, Vardiman J,. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol 2006; 19: 413-37. (Pubitemid 43884244)
9. De Stefano V, Fiorini A, Rossi E, et al. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis. Hepatology 2007; 45: 831-2. (Pubitemid 46450639)
10. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-8. (Pubitemid 40663494)
11. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-90. (Pubitemid 40570926)
12. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-61. (Pubitemid 40386783)
13. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-97. (Pubitemid 40544655)
14. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12. (Pubitemid 30214957)
15. Westbrook RH, Mufti G, Heneghan MA,. JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis: authors' reply. Aliment Pharmacol Ther 2011; 33: 496-7.
16. Qi X, Hu F, Yang Z, Han G, Fan D,. JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis. Aliment Pharmacol Ther 2011; 33: 495-6.
17. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528-34. (Pubitemid 44953658)
18. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88. (Pubitemid 17189972)
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60. (Pubitemid 37088507)
20. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34. (Pubitemid 27387172)
21. McCarthy N, McCarron SL, Langabeer SE,. Prevalence of the JAK2 V617F and MPL mutations in stroke, abdominal and peripheral venous thrombosis. Acta Haematol 2010; 124: 160-1.
22. Orr DW, Patel RK, Lea NC, et al. The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis. Aliment Pharmacol Ther 2010; 31: 1330-6.
23. Shetty S, Kulkarni B, Pai N, Mukundan P, Kasatkar P, Ghosh K,. JAK2 mutations across a spectrum of venous thrombosis cases. Am J Clin Pathol 2010; 134: 82-5.
24. Smira G, Gheorghe L, Iacob S, Coriu D, Gheorghe C,. Budd Chiari syndrome and V617F/JAK 2 mutation linked with the myeloproliferative disorders. J Gastrointestin Liver Dis 2010; 19: 108-9.
25. Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 2010; 51: 210-8.
26. Xavier SG, Gadelha T, Pimenta G, et al. JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci 2010; 55: 1770-7.
27. Tondeur S, Boutruche S, Biron-Andreani C, Schved JF,. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study. Thromb Haemost 2009; 101: 787-9.
28. Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009; 151: 167-75.
29. Goulding C, Uttenthal B, Foroni L, et al. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. Int J Lab Hematol 2008; 30: 415-9.
30. Colaizzo D, Amitrano L, Tiscia GL, et al. Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome. Blood Coagul Fibrinol 2008; 19: 459-62.
31. Bayraktar Y, Harmanci O, Buyukasik Y, et al. JAK2V617F mutation in patients with portal vein thrombosis. Dig Dis Sci 2008; 53: 2778-83.
32. Colaizzo D, Amitrano L, Guardascione MA, Balzano A, Margaglione M,. Janus kinase-2 mutation, cirrhosis and splanchnic vein thrombosis. Eur J Gastroenterol Hepatol 2008; 20: 245-6. (Pubitemid 351317366)
33. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008; 111: 4922-9.
34. Regina S, Herault O, D'Alteroche L, Binet C, Gruel Y,. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007; 5: 859-61. (Pubitemid 46563588)
35. Colaizzo D, Amitrano L, Iannaccone L, et al. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet 2007; 44: 412-6. (Pubitemid 46953726)
36. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-14. (Pubitemid 46563568)
37. Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5: 55-61. (Pubitemid 44921067)
38. McMahon C, Abu-Elmagd K, Bontempo FA, Kant JA, Swerdlow SH,. JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses. Am J Clin Pathol 2007; 127: 736-43.
39. Smalberg JH, Darwish Murad S, Braakman E, Valk PJ, Janssen HL, Leebeek FW,. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 2006; 91: 1712-3. (Pubitemid 46032973)
40. Boissinot M, Lippert E, Girodon F, et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 2006; 108: 3223-4.
41. Gangat N, Wolanskyj AP, Tefferi A,. Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications. Eur J Haematol 2006; 77: 327-33. (Pubitemid 44337326)
42. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130: 2031-8. (Pubitemid 43816970)
43. Grandone E, Colaizzo D, Tiscia GL, et al. Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation. Thromb Haemost 2008; 99: 640-2. (Pubitemid 351549306)
44. Karimi O, Crusius JB, Coucoutsi C, et al. JAK2 V617F mutation is not involved in thromboembolism in IBD. Inflamm Bowel Dis 2008; 14: 1606-7.
45. Abel GA, DeAngelo DJ, Connors JM, Sholl LM, McCaffrey RP, Longtine JA,. Clinical JAK2V617F mutation testing: limited utility for general hospital patients with venous and arterial thromboses in common locations. Am J Hematol 2008; 83: 519-20. (Pubitemid 351742809)
46. Garces-Eisele J, Gonzalez-Carrillo ML, Reyes-Nunez V, Ruiz-Arguelles GJ,. Primary thrombophilia in Mexico VII: the V617F mutation of JAK2 is not a frequent cause of thrombosis. Hematology 2008; 13: 244-6.
47. Rossi D, Cresta S, Destro T, et al. JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia. Br J Haematol 2007; 138: 813-4. (Pubitemid 47313208)
48. Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009; 113: 5617-23.
49. Janssen HL, Leebeek FW,. JAK2 mutation: the best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis? Hepatology 2006; 44: 1391-3. (Pubitemid 44953641)
50. Kwaan HC,. JAK2V617F: better diagnostic tool than marrow? Blood 2008; 111: 4835-6.
51. De Stefano V, Teofili L, Leone G, Michiels JJ,. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997; 23: 411-8. (Pubitemid 27501780)
52. Zocco MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009; 51: 682-9.
53. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-27.
54. Valla DC,. Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West. J Gastroenterol Hepatol 2004; 19: S204-11.